A Phase 1/2a, First-in-Human, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Therapeutic Activity of Single Ascending Doses of KLS-2031 Administered by Transforaminal Epidural Injection in Patients With Neuropathic Pain From Lumbosacral Radiculopathy
Latest Information Update: 01 Aug 2024
At a glance
- Drugs KLS 2031 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions; First in man
- Sponsors Kolon Life Science
Most Recent Events
- 25 Jul 2024 Status changed from active, no longer recruiting to completed.
- 05 Oct 2022 Planned End Date changed from 30 Sep 2023 to 30 Oct 2023.
- 05 Oct 2022 Planned primary completion date changed from 30 Sep 2022 to 30 Oct 2022.